Incyte

ABOUT

A global biopharmaceutical company on a mission to Solve On., Incyte follows the science to find solutions for patients with unmet medical needs through the discovery, development and commercialization of proprietary therapeutics.

Since 2002, Incyte has remained committed to the relentless pursuit of science that can improve the lives of patients and make a difference in healthcare. Incyte’s unique expertise in medicinal chemistry and biology has enabled us to establish a portfolio of first-in-class medicines for patients and a strong pipeline of products in Oncology and Inflammation & Autoimmunity, including 24 clinical compounds in development.

Headquartered in Wilmington, Delaware, Incyte has operations in North America, Europe and Asia. We have more than 2,500 employees, including more than 1,000 world-class scientists, who are committed to discovering first-in-class medicines for patients who previously had limited treatment options.

For more information about Incyte, please visit us at www.Incyte.com. Follow Incyte on X, LinkedIn, Facebook and Instagram.

1801 Augustine Cut-off, Wilmington, DE 19803
NEWS
This year wasn’t big for mergers and acquisitions in biopharma, particularly compared to 2015 and 2016.
Astra and Incyte are pushing forward on the development of immunotherapy combination treatments.
Incyte picked up MGA012 and the exclusive rights to develop the drug worldwide.
Incyte has been at the forefront of the IDO race with its candidate epacadostat.
Incyte has levelled charges of stealing company secrets against the founders of Flexus Biosciences over the hiring of Incyte’s former CSO who had access to Incyte’s scientific research.
AWARDS
  • 2025 BPTW Badge - RBG.png
JOBS
IN THE PRESS